You are here

Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.

Last updated on May 12, 2018

FOR MORE INFORMATION
Study Location
Nagoya, Aichi, 462-0831 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Depression
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with schizophrenia or any other psychotic disorder

- Patients with history or presence of bipolar disorder

NCT00225524
Pfizer
Completed
Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Depression
NCT00225485
All Genders
65+
Years
Multiple Sites
Depression, Depressive Disorder, Major Depressive Disorder
NCT00369343
Females
40+
Years
Multiple Sites
Depression
NCT00225511
All Genders
20+
Years
Multiple Sites
Depression
NCT00225524
All Genders
20+
Years
Multiple Sites
Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.
Phase III Long-Term Administration Study of Effexor XR for the Treatment of Depression
Phase III long-term safety study of Effexor XR in patients with major depression.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Depression
Drug: Effexor XR
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
Not Provided
Not Provided

Inclusion Criteria:

  • Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816)

Exclusion Criteria:

  • Patients with schizophrenia or any other psychotic disorder
  • Patients with history or presence of bipolar disorder
Sexes Eligible for Study: All
20 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00225524
0600B1-818
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
May 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now